GV, Tencent and Gilead Sciences will exit the vaccine and infectious disease drug developer in an initial public offering sized at about $110m.

Vaccitech, a UK-based vaccine developer that counts corporates Tencent, Alphabet, and Gilead Sciences as investors, will raise about $110m when it begins trading on the Nasdaq Global Market today.

The company will issue 6.5 million American Depositary Shares (ADSs), each representing one ordinary share. It priced them at $17.00 each, at the midpoint of the IPO’s $16 to $18 range.

Founded in 2016, Vaccitech initially aimed to develop a universal flu vaccine but the most fundamental impact its technology has…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn